

Scientific background

Covid-19 anti-docking strategy for the throat

Virus-reducing preventative treatment: gargling H_2O_2 /alcohol at set intervals

Coronaviruses have long been endemic and are known to be the cause of winter infections among children, for example. SARS-CoV-2 is a mutation caused by transmission from bats to pigs – and its high level of infectiousness and pathogenicity now also poses a threat to the human body.

The primary means of infection is the inhalation of droplets released by infected people when they cough or sneeze.

These droplets contain the virus. Due to the physiological centrifugation effect that occurs when they are breathed in, the viruses come into contact with the mucous membrane in the nose and duly accumulate in the nose and throat area.

For reasons relating to respiratory physiology, the number of viruses that reach the lungs directly can be classed as relatively small. This is because hardly any free viruses find their way into the alveoli without first contacting the mucous membranes in the nose and throat area or in the bronchial system.

A viral infection fundamentally depends on the number and pathogenicity of viruses entering the body, as well as the competence and dimensions of the human immune system.

Whenever a new virus appears, the non-specific and – if we consider the primary means of infection with SARS-CoV-2 – the local immune system comprising the mucous membranes in the nose and throat area or in the bronchial system acquire great significance. The defensive system is of primary importance in this context, as it is capable of inhibiting virus replication in the mucous membranes. Additional protection is provided by the non-specific cellular macrophage system, which is activated by alpha- and beta-interferons (for instance) and triggers an inflammatory defensive response that is capable of eliminating viruses.

In fighting SARS-CoV-2 viruses via targeted external measures, we can build on the physiological

mechanisms of the immune defence system by using a particular feature of coronaviruses to our advantage.

Coronaviruses are enveloped viruses that use the spike protein on their surface to penetrate into the host cell and dock onto the receptors of a mucous membrane cell (angiotensin-converting enzyme 2: HCoV-NL63, SARS-CoV, sialic acid HCoV-OC43), which in turn enables the fusion between the viral envelope and the cell membrane. The spike protein is also the structure that lends coronaviruses their familiar appearance when viewed under an electron microscope and is indeed the inspiration behind their name.

A team of researchers at the University of Texas has succeeded in decoding the structure of the spike protein and proving that, while it uses the same 'unfolding mechanism' as other coronaviruses, it docks onto the ACE2 receptor of the mucous membrane cells with around 20 times the intensity of spike proteins in previously known coronaviruses (McLellan et al., 2020). This is what makes it more infectious among humans. These findings suggest that it is crucially important to disrupt or prevent the docking mechanism, for example via oxidation with H_2O_2 or C_2H_5OH , as virus replication is almost impossible to influence later on in the process.

In the course of docking, which is currently believed to take 2–6 hours (Ziebuhr J., 2008), the spike protein changes its structure and enters into an energetically metastable state. As the process continues, the spike protein is proteolytically split into S1 and S2 proteins.

Two components of the S2 peptide, known as heptad repeats 1 and 2 respectively, are of particular significance. During fusion activation, HR1 and HR2 interactions in the spike protein trimer help form a compact bundle structure (six-helix bundle) typically seen in the stable post-fusion state of the spike protein. Not only can the initial metastable ener-

getic state of the spike protein be used to destroy the protein via oxidation mechanisms, the HR1 and HR2 interactions can be specifically inhibited and the entry of the virus into the host cell prevented as a result (Ziebuhr J., 2008).

This has inspired the development of an anti-docking strategy involving systematic virus-reducing gargling – a simple measure anyone can perform correctly in order to reduce the viral load in the nose and throat area, support the body's defence mechanisms and prevent these from being overwhelmed.

A 1.5–2% H_2O_2 solution was chosen for the oxidation mechanism as it is capable of inhibiting the docking process and virus replication.

No toxic effect on mucous membrane cells is to be anticipated with this H_2O_2 concentration. Instead, targeted oxidative processes are supported through peroxiredoxins that are present in large quantities in every somatic cell and use H_2O_2 for the oxidation of target proteins such as virus proteins (German Cancer Research Center, Dick T. P., 2014). Another effect that destroys spike proteins is provided by an alcohol component featuring an initial concentration of 70–90%, which is then diluted to 6–8% by volume in the solution.

It is therefore anticipated that the continuous application of a corresponding gargling solution containing H_2O_2 and alcohol at intervals of 4–6 hours can sufficiently reduce the viral load in the throat so as to prevent severe illness caused by the body being flooded with viruses originating from the throat.

10. Bibliography

Scientific sources:

'Gurgeln21 initiative – Covid-19 anti-docking strategy for the throat'

JJaneway C. A., Travers P., Walport M., Shlomchik M.: Immunologie, 2002, 5th edition

Lai M. M. C., Perman S., Anderson L. J.: Coronaviridae, 2007

McLellan J. et al./Univ. of Texas at Austin, 2020

Sidell S. G., Ziebuhr J., Snijder E. J.: Coronaviruses, toroviruses and arteriviruses, 2005

Sobotta M. C., Liou W., Stöcker S., Talwar D., Oehler M., Ruppert T., Scharf A. N., Dick T. P.: Peroxiredoxin-2 and STAT3 form a redox relay for H₂O₂ signaling, 2014

Wendtner C. in Cyranoski D. (12 May 2020) 'Profil eines Killers', from https://www.spektrum.de/news/woher-kommt-das-coronavirus-und-was-tut-es-als-naechstes/1733810?utm_source=pocket-newtab-global-de-DE

Ziebuhr J.: Coronavirus replicative proteins, 2008

Tvarogová J., Madhugiri R., Bylapudi G., Ferguson L. J., Karl N. and Ziebuhr J. 2019. Identification and characterization of a human coronavirus 229E nonstructural protein 8-associated RNA 3'-terminal adenylyltransferase activity. *J. Virol.* 93:e00291-19.

Melior H., Li S., Madhugiri R., Stötzel M., Azarde-rakhsh S., Barth-Weber S., Baumgardt K., Ziebuhr J. and Evguenieva-Hackenberg E. 2019. Transcription attenuation-derived small RNA rTrpL regulates tryptophan biosynthesis gene expression in trans. *Nucleic Acids Res.* 47:6396-6410.

Madhugiri R., Karl N., Petersen D., Lamkiewicz K., Fricke M., Wend U., Scheuer R., Marz M. and Ziebuhr J. 2018. Structural and functional conservation of cis-acting RNA elements in coronavirus 5'-terminal genome regions. *Virology* 517:44-55.

Müller C., Hardt M., Schwudke D., Neuman B. W., Pleschka S. and Ziebuhr J. 2018. Inhibition of

cytosolic phospholipase A2alpha impairs an early step of coronavirus replication in cell culture. *J. Virol.* 92:e01463-17.

Kindler E., Gil-Cruz C., Spanier J., Li Y., Wilhelm J., Rabouw H. H., Züst R., Hwang M., V'Kovski P., Stalder H., Marti S., Habjan M., Cervantes-Barragan L., Elliot R., Karl N., Gaughan C., van Kuppeveld F. J., Silverman R. H., Keller M., Ludewig B., Bergmann C. C., Ziebuhr J., Weiss S. R., Kalinke U. and Thiel V. 2017. Early endonuclease-mediated evasion of RNA sensing ensures efficient coronavirus replication. *PLoS Pathog.* 13:e1006195

Snijder E. J., Decroly E. and Ziebuhr J. 2016. The nonstructural proteins directing coronavirus RNA synthesis and processing. *Adv. Virus Res.* 96:59-126

Lemmermeyer T., Lamp B., Schneider R., Ziebuhr J., Tekes G. and Thiel H. J. 2016. Characterization of monoclonal antibodies against feline coronavirus accessory protein 7b. *Vet. Microbiol.* 184:11-19.

de Groot R. J., Baker S. C., Baric R. S., Brown C. S., Drosten C., Enjuanes L., Fouchier R. A., Galiano M., Gorbalenya A. E., Memish Z. A., Perlman S., Poon L. L., Snijder E. J., Stephens G. M., Woo P. C., Zaki A. M., Zambon M. and Ziebuhr J. 2013. Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group. *J. Virol.* 87:7790-7792.

Züst, R., Cervantes-Barragan L., Habjan M., Maier R., Neuman B. W., Ziebuhr J., Szretter K. J., Baker S. C., Barchet W., Diamond M. S., Siddell S. G., Ludewig B. and Thiel V. 2011. Ribose 2'-O-methylation provides a molecular signature for the distinction of self and non-self mRNA dependent on the RNA sensor Mda5. *Nature Immunol.* 12:137-43.

Ulferts R. and Ziebuhr J. 2011. Nidovirus ribonucleases: structures and functions in viral replication. *RNA. Biol.* 8:295-304.

Ulferts R., Imbert I., Canard B. and Ziebuhr J. 2010. Expression and functions of SARS coronavirus replicative proteins, p. 75-98. In Lal S. K. (ed.), Molecular biology of the SARS-coronavirus. Springer, Berlin & Heidelberg.

Ziebuhr J. 2008. Coronavirus replicative proteins, p. 65-81. In Perlman S., Gallagher T. and Snijder E. J. (ed.), Nidoviruses. ASM Press, Washington, DC.

Ziebuhr J., Schelle B., Karl N., Minskaia E., Bayer S., Siddell S. G., Gorbalenya A. E. and Thiel V. 2007. Human coronavirus 229E papain-like proteases have overlapping specificities but distinct functions in viral replication. *J. Virol.* 81:3922-32.

Minskaia E., Hertzog T., Gorbalenya A. E., Campanacci V., Cambillau C., Canard B. and Ziebuhr J. 2006. Discovery of an RNA virus 3'->5' exoribonuclease that is critically involved in coronavirus RNA synthesis. *Proc. Natl. Acad. Sci. USA* 103:5108-13.

Seybert A., Posthuma C. C., van Dinten L. C., Snijder E. J., Gorbalenya A. E. and Ziebuhr J. 2005. A complex zinc finger controls the enzymatic activities of nidovirus helicases. *J. Virol.* 79:696-704.

Ziebuhr J. 2004. Molecular biology of severe acute respiratory syndrome coronavirus. *Curr. Opin. Microbiol.* 7:412-9.

Anand K., Ziebuhr J., Wadhwani P., Mesters J. R. and Hilgenfeld R. 2003. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. *Science* 300:1763-7.

Date: 11/2021

Responsible for content: Dr Achim Neumayr

2021 © Content and concept: Dr Achim Neumayr

2021 © Design/PR: mwi | musselmann wulz identity oHG, www.mwi.one.